博雅生物近期股价震荡下行，高管薪酬与业绩表现受关注

Group 1 - The core issue revolves around corporate governance and performance concerns at Boya Bio-Pharmaceutical (300294), with investor skepticism regarding executive pay amidst operational losses [1] - The company emphasized its focus on the blood products core business, indicating uncertainty in external mergers and acquisitions, while disclosing that the controlling shareholder, China Resources Pharmaceutical, has no new holding plans [1] - Boya Bio-Pharmaceutical's net profit for 2025 is expected to decline significantly, underperforming compared to its peers among six listed companies [1] Group 2 - Boya Bio-Pharmaceutical's stock price has shown a downward trend, closing at 22.33 yuan on February 12, 2026, with a daily drop of 0.76% and a cumulative decline of 0.53% over the past five days [2] - The stock has experienced a 4.08% decline over the past 20 days, with a net outflow of 4.74 million yuan in principal funds on the latest trading day [2] - The stock's short-term technical support level is at 22.01 yuan, while the resistance level is at 23.75 yuan, indicating weaker performance compared to the pharmaceutical and biotechnology sector, which fell by 0.44% [2]